IFNG and neuroblastoma: As with experiments testing neuroblastoma/monocyte CM, we discovered that lenalidomide, at clinically achievable concentrations [16, 32], prevented IL-6 suppression of IL-2-mediated activation of NK cell cytotoxicity, ADCC, and IFNγ secretion.